Business Context and Reporting Period
This Form 8-K was filed by AtriCure, Inc. on August 7, 2007, reporting material events occurring on August 7 and August 9, 2007. The filing primarily details the acquisition of a specific product line from CooperSurgical, Inc. and references the company's financial results for the second quarter ended June 30, 2007.
Key Financial Metrics and Transaction Details
The filing discloses a specific acquisition transaction but does not provide comprehensive financial statements (revenue, profit, cash flow, or margins) within the text of this report; those figures are contained in a referenced press release.
- Acquisition Cost: Total consideration of $3,661,536 for the Frigitronics CCS-200 product line.
- Cash Payment: $3,244,244 paid on August 8, 2007.
- Debt Obligation: $417,922 payable via an unsecured promissory note bearing 5% interest.
- Repayment Terms: The note is due within three days of Cooper completing defined manufacturing services and delivering remaining assets.
Material Changes and Agreements
AtriCure entered into a Bill of Sale and Assignment Agreement with CooperSurgical, Inc. to acquire the Frigitronics CCS-200 product line, including a console, reusable probes, inventory, and manufacturing equipment. This product is used for cardiac tissue ablation during open-heart procedures.
Additionally, a Non-Competition Agreement was executed with the following restrictions for eight years:
- CooperSurgical is restricted from selling cardiovascular cryosurgical products worldwide.
- AtriCure is restricted from selling ophthalmic or gynecological cryosurgical products worldwide.
A limited worldwide license to use the Frigitronics trademark and CCS-200 name in combination with AtriCure was granted for a maximum of four years.
Outlook, Risks, and Management Commentary
The filing references a press release issued on August 9, 2007, regarding Q2 2007 results, but the text of this 8-K does not contain specific guidance, outlook, or management commentary on those results. The filing notes that CooperSurgical will manufacture and supply 23 consoles and 40 probes to AtriCure between September and December 2007, along with warranty and replacement services.
Risks and Contingencies: The filing does not explicitly list risks beyond the standard legal disclaimers. The transaction creates a short-term debt obligation contingent on the completion of manufacturing services by the seller.
Investor Verification Checklist
- Verify the Q2 2007 financial results (revenue, net income, cash flow) in the referenced press release (Exhibit 99.1), as they are not detailed in this 8-K text.
- Confirm the impact of the $3.66 million cash outflow on the company's current liquidity position.
- Review the full text of the Bill of Sale (Exhibit 10.1) and Non-Competition Agreement (Exhibit 10.2) for specific covenants and termination clauses.
- Monitor the delivery schedule for the 23 consoles and 40 probes to ensure the promissory note repayment trigger is met.